Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 95.2%

Neg 95.2% Neu 0% Pos 0%

Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $12 to $7.